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Spinocerebellar ataxia type 1 (SCA1) is a dominantly inherited progressive neurological disorder characterized by neu- 
ronal degeneration and reactive gliosis in the cerebellum, brainstem, spinocerebellar tracts, and dorsal columns. Multiple 
system atrophy is a sporadic progressive neurological disorder with degeneration and gliosis in the basal ganglia, cerebel- 
lum, brainstem, and spinal autonomic nuclei, and with argyrophilic glial cytoplasmic inclusions. We describe 4 members 
of a family with the SCAl mutation and a dominantly inherited progressive ataxia in which autopsy examination of 1 
member showed neuropathological changes typical of multiple system atrophy, including glial cytoplasmic inclusions. In 
this patient, magnetic resonance imaging revealed marked brainstem and cerebellar volume loss and mild supratentorial 
generalized volume loss. Positron emission tomography with [ 18F]fluorodeoxyglucose revealed widespread hypometabo- 
lism in a pattern found in sporadic multiple system atrophy and not in dominantly inherited olivopontocerebellar 
atrophy. Positron emission tomography with (llC]flumazenil revealed normal benzodiazepine receptor distribution vol- 
umes, similar to those seen in sporadic multiple system atrophy. Two other family members still living had similar 
changes in the imaging studies. The findings in this family suggest that the SCAl gene mutation can result in a disorder 
similar to multiple system atrophy, both clinically and neuropathologically. 
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Olivopontocerebellar atrophy (OPCA) is a progressive 
neurological disease characterized clinically by cerebel- 
lar ataxia and neuropathologically by neuronal degener- 
ation and gliosis in the inferior olives, pons, and cere- 
bellum [ 1-41. The disorder occurs sporadically and 
with hereditary transmission, in both autosomal domi- 
nant and autosomal recessive forms. Thus far, genetic 
studies on patients with dominantly inherited OPCA 
have identified five independent responsible genetic 
loci [5-91. Most patients become symptomatic in mid- 
dle age with gradually evolving incoordination of gait 
followed by difficulty with speech and limb move- 
ments. Examination reveals ataxia affecting oculo- 
motor, bulbar, and limb musculature and variable in- 
volvement of corticobulbar and corticospinal systems, 
including spasticity of speech and of the limbs, hyper- 
active muscle stretch reflexes, and extensor plantar re- 
sponses. 
Multiple system atrophy (MSA) is a sporadic pro- 
gressive neurodegenerative disease manifested clinically 
by combinations of cerebellar, pyramidal, extrapyrami- 
dal, and autonomic symptoms and signs [lo, 111. The 
neuropathological changes include neuronal loss and 
gliosis within the inferior olives, pons, cerebellum, sub- 
stantia nigra, caudate nucleus, putamen, globus pal- 
lidus, and intermediolateral columns of the spinal cord 
[ 121. A recently described, distinctive neuropathologi- 
cal feature of MSA consisted of oligodendroglial [13- 
181 and neuronal [17, 19, 201 intracytoplasmic and 
intranuclear argyrophilic inclusions containing accu- 
mulations to tubular structures. The glial cytoplasmic 
inclusions (GCIs), which show positive immunostain- 
ing for ubiquitin and tau [14, 151, have been detected 
in striatonigral degeneration (SND), Shy-Drager syn- 
drome (SDS), sporadic olivopontocerebellar atrophy 
(sOPCA) [21, 221, corticobasal degeneration [23], and 
hereditary OPCA (in 1 patient) [14]. GCIs were not 
found in 15 other patients with hereditary OPCA rnen- 
tioned by Quinn and Marsden [ l  11, 1 patient de- 
scribed by Costa and colleagues [17], or 9 patients 
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studied by Abe and coworkers [24) .  GCIs were not 
found in a large number of neurological control sub- 
jects, including patients with Parkinson’s disease or 
progressive supranuclear palsy [ 1 11. 
Although MSA is considered to be a sporadic and 
not a hereditary disorder, dominantly inherited ataxia 
at times is associated with neuropathological changes 
in the basal ganglia, as in OPCA type V of Konigsmark 
and Weiner [25, 261, and in Machado-Joseph disease 
[27]. We report here the study of a family with the 
spinocerebellar ataxia type 1 (SCA1) mutation present- 
ing with a dominantly inherited progressive neurode- 
generative disease involving ataxia, dystonia, autonomic 
dysfunction, and peripheral neuropathy. Clinical neu- 
rological, speech, and neuropsychological evaluations 
were supplemented with anatomical (magnetic reso- 
nance imaging [MRI] or computed tomography [CT]) 
and functional (positron emission tomography [PET]) 
imaging studies. We compared the functional imaging 
studies in this family with those obtained from normal 
control subjects, from patients with sporadic MSA, and 
from other families with dominantly inherited OPCA 
(dOPCA). 
Materials and Methods 
Clinical Eualudtio ns 
The studies were approved by the Institutional Review 
Board, and informed consent was obtained from each sub- 
ject. The patients were evaluated by questions for medical 
and neurological histories, physical examinations, neurologi- 
cal examinations, perceptual speech evaluations, neuropsy- 
chological testing, MRI or CT, and PET. Testing of blood 
samples for the SCAl mutation was performed by a com- 
mercial laboratory. Our methods of examining speech in 
patients with ataxia are described in other publications (28- 
301. 
The neurological disorder in this family was transmitted 
in a pattern suggesting autosomal dominant inheritance (Fig 
1). The disorder affected both males and females, was ob- 
served in three successive generations, and was expressed only 
in the offspring of affected persons. The disease presented 
clinically with a progressive cerebellar disorder. In 2 patients 
in their eighth decade (Patients 1 and 2), the cerebellar disor- 
der was associated with impotence, bladder dysfunction, and 
signs of pyramidal and extrapyramidal dysfunction. Two ad- 
ditional patients in this family had cerebellar disorders begin- 
ning in their fifth decade but no symptoms or signs of extra- 
pyramidal or autonomic dysfunction, although both were in 
an early phase of the disorder. The clinical finding of cerebel- 
lar involvement was buttressed by anatoniical imaging studies 
showing both brainstem and cerebellar atrophy (Fig 2). All 4 
patients had evidence of mild peripheral neuroparhy affecting 
both sensory and motor fibers. 
Positron Emission Tomogrdphy 
Studies were performed with rhe subjects lying supine and 
awake in a quite room, with eyes open and ears unoccluded 
and alert but not speaking from 5 minutes before injection 
a& 31 27 23 25 23 21 5 
Fig 1. Pedigree showing five generatiom o f  the fdmily with 
the SCAI mutation. The injirmation in this pedigree was 
provided by 6famil3, members in Generations 3 and 4. 
Filled symbols indicate affected individuals. Generation I :  
Both parents died in their 20s o f  unknown cuuses without 
known neurological disorders. Generation 2: The affected indi- 
vidual developed u cerebellm disorder at age 60 and died of 
u cerebral hemorrhage at uge 68. The sibling died with bron- 
chial asthma and had no neurological disorder. Generation 3: 
The affected sibling o f  Patients 1 and 2 developed a cerebel- 
lar disorder in his mid-50s and wus confined to a wheelchair 
at the time of death. Generation 4: Three siblings of Patient 
4 died between ages 1 and 2 of unknown causes. We did not 
examine the affected daughter of Patient 2. 
Fig 2. Magnetic resonance image in the sagittal plane of 
Patient I ,  a D-year-old man, showing zerebellur and brain- 
stem atrophy. 
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Tabk 1. Age and Sex Distributions of Subjects Studied with Positron Emission Tomographya 
[ lXF]Fluorodeoxyglucose Studies ["C]Flumazenil Studies 
Normal Normal 
Controls SCAl dOPCA MSA Controls dOPCA MSA 
Men 2 10 14 19 6 11 11 
Women 1 7 12 32 8 8 9 
Total 3 17 26 51 14 19 20 
Age (yr, range) 45-72 31-66 47-82 19-76 31-66 44-75 42-82 
Age (yr, mean ? SD) 62 5 15 46 ? 13 63 ? 8 44 ? 17 50 i- 14 63 i- 9 61 ? 10 
'The 3 patients with the SCAl mutation were studied with both ['8F]fluorodeoxyglucose and ["C]flumazenil. Analysis of covariance was 
used to adjust for differences in age and sex among the four groups in the data analysis. 
SCAl = patients with the spinocerehellar ataxia type 1 mutation; dOPCA = dominantly inherited olivopontocerebellar atrophy from different 
families; MSA = multiple system atrophy; SD = standard deviation. 
until completion of the scan. The subjects fasted for 4 hours 
before the PET studies. A catheter was placed in a radial 
artery for blood sampling. PET scans were performed follow- 
ing intravenous injection of 22 ? 2 mCi of [ "C]flumazenil 
(FMZ) and, 90 minutes later, 10 mCi of ['8F]Auorodeoxy- 
glucose (FDG). All subjects were imaged with a Siemens/ 
CTI 931 /08-12 scanner, which has an intrinsic in-plane res- 
olution of 5.5-mm full width at half maximum (FWHM) 
in the center of the field of view and an axial resolution of 
7.0-mm FWHM. The reconstructed resolution is 9.0-mm 
FWHM at the center of the field of view. Fifteen planes 
with a 6.75-mm center-to-center separation were imaged si- 
multaneously. Attenuation correction was calculated by the 
standard ellipse method. 
The studies with FMZ were performed as a 60-minute 
sequence of 15 scans and used to measure benzodiazepine 
(BDZ) receptor density as assessed by ligand distribution vol- 
ume (DV). The latter is linearly related to the density of 
available receptor sites divided by the ligand dissocation con- 
stant (B,,,ax,/KD). The studies with FMZ also yield regional 
values for ligand transport ( K ) ,  which is highly correlated 
with flow since the single-pass extraction fraction for FMZ 
is greater than 50% [31]. The methods of using FMZ for 
BDZ receptor binding, including the assumptions, limita- 
tions, and performance of the agent, have been published 
[31-331. The studies with FDG were performed as two in- 
terleaved image sets acquired 30 to 90 minutes after injec- 
tion, and data were quantified according to the static scan 
method of Hutchins and associates [34]. Radioactive fiducial 
markers [31] were used to register all frames of the dynamic 
FMZ scan and to register the FDG scan to the FMZ scan. 
Volume-of-interest (VOI) data were acquired from the ce- 
rebral cortex, caudate nucleus, putamen, thalamus, cerebellar 
hemispheres, cerebellar vermis, and brainstem, as described 
previously [35]. VOI placement was determined on images 
of FMZ DV, which provide superb definition of gray matter 
structures, and the same placement was used on images of 
FMZ transport ( K )  and local cerebral metabolic rate for glu- 
cose (1CMRglc). 
DATA ANALYSIS. Data from PET studies with FDG in Pa- 
tients l ,  2, and 3 in this family were compared with data 
from 17 patients with dOPCA without known multiple sys- 
tem degeneration from many different families, 26 patients 
with MSA, and 51 normal control subjects (Table 1). Data 
from PET studies with FMZ in the same 3 patients in this 
family were compared with data from 14 patients with 
dOPCA without known multiple-system degeneration from 
many different families, 19 patients with MSA, and 20 nor- 
mal control subjects (see Table 1). Some of the FDG and 
FMZ data from dOPCA, MSA, and normal control groups 
have been published [35, 361. 
Distributions of three measures-absolute level of 
ICMRglc, FMZ ligand inflow ( K ) ,  and FMZ DV-were 
compared in seven regions of the brain. Analysis of covari- 
ance was used to adjust for differences in the age and sex 
distributions of the four groups, and to provide two-sided 
statistical analyses comparing the means of the study subjects 
with the means of the dOPCA, MSA, and control groups. 
When a significant ( p  < 0.05) interaction was found be- 
tween either age or sex and study group, a separate covariate 
adjustment for age and sex was applied within each group. 
Since the comparison groups differed considerably in age, 
two additional analyses were run restricting all subjects in 
the comparison groups to (a) all those age 40 or older utiliz- 
ing adjusted means and (b) all subjects age 45 or older utiliz- 
ing unadjusted means. A covariance adjustment was not 
needed for the analysis in (b) since the age means were simi- 
lar in the four groups. These analyses yielded similar means, 
suggesting that the covariance adjustments were reasonable. 
His to pathology 
One patient (Patient 1) was examined neuropathologically. 
Sections were taken from various cortical areas, anterior and 
posterior basal ganglia, thalamus, several levels of the brain- 
stem, and cerebellum. They were stained with cresyl violet- 
Lux01 fast blue-eosin (CV-LFB-E), phosphotungstic acid he- 
matoxylin (PTAH), and Bielschowsky's silver stain. Patho- 
logical changes, including neuronal loss and gliosis, were 
scored as follows: 0 = normal; + = mild; ++ = moderate; 
+++ = severe. 
Immunocytochernisty 
Paraffin-embedded, 5-pm-thick sections were immuno- 
stained with the avidin-biotin-peroxidase complex (ABC) 
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method [37] with a Vectastain ABC kit (Vector, Burlingame, 
CA). The following primary antibodies were applied: poly- 
clonal rabbit anti-chicken tau (1 : 100) (Sigma Chemical, St. 
Louis, MO); polyclonal rabbit anti-human ubiquitin (1 : 
100) (Dako, Carpenteria, CA); monoclonal phosphorylated 
neurofilament ( 1  : 250) (Sternberger Monoclonals, Baltimore, 
MD); monoclonal mouse anti-human beta-amyloid (1 : 100) 
(Dako, Carpenteria, CA); and polyclonal rabbit anti-human 
glial fibrillary acidic protein (GFAP) (1 : 250) (Sigma Chemi- 
cal, St. Louis, MO). 
Nonspecific binding was blocked by pretreatment with a 
blocking kit (Vector). Negative control samples were per- 
formed by omitting the primary or secondary antibody. Sec- 
tions were incubated with the required primary antibody fol- 
lowed by the secondary reagent, including biotinylated anti- 
rabbit or anti-mouse IgG for 30 minutes and then with 
ABC. The sections were then subjected to peroxidase reac- 
tion containing freshly prepared 0.02% 3,3 ' diamino benzi- 
dine tetrachloride and 0.05% hydrogen peroxide in 0.05 M 
Tris-hydrochloric acid buffer at p H  7.6 for 10 minutes at 
room temperature. Staining was performed on a Histostainer 
Ig instrument (Leica, Deerfield, IL). 
Results 
Clinical Summaries 
PATIENT 1. The patient was well until the age of 60 years 
when he progressively had difficulty walking, causing him to 
fall frequently. At age 64 he experienced dysarthria and then 
incoordination of his hands, with impaired handwriting. He 
noted difficulty swallowing solids beginning around the age 
of 68. His incoordination slowly progressed and he began 
using a wheelchair consistently by age 69. H e  denied diffi- 
culty with bladder or bowel function, but had been sexually 
impotent since age 57 or 58. He had non-insulin-dependent 
diabetes mellitus that was well controlled and hypertension, 
both of which were detected at age 63. H e  had a family 
history of a progressive ataxia affecting at least three genera- 
tions (see Fig l). 
The most recent physical examination was when the pa- 
tient was 73 years old, 4 months prior to death, and at that 
time he was confined to a wheelchair because of severe ataxia 
of the limbs and trunk. The blood pressure was 140186 mm 
Hg while he was sitting. Easily provoked and inappropriate 
laughter suggested a pseudobulbar affect. Abnormalities of 
extraocular movements including square-wave jerks on pri- 
mary gaze, saccadic pursuits, and unsustained nystagmus on 
lateral gaze were found. Occasionally facial grimaces and in- 
voluntary tongue movements appeared. Rapidly alternating 
tongue movements were moderately impaired. H e  had a 
moderately severe mixed dysarthria with ataxic and dystonic 
components. Moderately severe ataxia was evident in the 
limbs, with a proximal kinetic tremor on finger-nose-finger 
testing, and a moderate degree of ataxia on heel-knee-shin 
testing. Rapidly alternating limb movements were slow and 
dysrhythmic. Resistance to passive manipulation was normal, 
even with activation. The deep tendon reflexes were graded 
at 3 (on a scale of 0-4) except for the ankle reflexes, which 
were grade 2. The plantar responses were flexor. Sensory ex- 
amination revealed decreased light touch and pinprick sensa- 
Table 2. Neuropsychological Test Results" of 3 Patients with 
the SCAl Mutation 
Patient No. Ageb (yr) Sex FSIQ PIQ MQ 
1 72  Male 79 74 80 
2 68 Male 79 66 71 
3 45 Female 90 87 96 
'Wechsler Adult Intelligence Scale was used to determine full-scale 
and performance intelligence quotients; Wechsler Memory Scale, to 
determine memory quotient. 
hAge refers to the time of neuropsychological testing. 
FSIQ = full-scale intelligence quotient; P I Q  = performance intelli- 
gence quotient; M Q  = memory quotient. 
tions in a stocking distribution in the lower extremities up 
to the midcalf region. Position and vibration senses were 
intact. The patient could stand with assistance but was too 
unsteady to walk. The patient died at age 74 with sepsis and 
respiratory failure coupled with diabetic ketoacidosis. 
Peripheral nerve conduction studies at age 68 revealed 
markedly reduced conduction velocities in sensory nerves and 
moderate slowing in motor nerves with electromyographic 
evidence of chronic denervation in the muscles of both legs. 
Neuropsychological testing at age 72 revealed scores at  the 
lower end of the normal range to below normal (Table 2). 
The patient was not tested for the SCAl mutation. MRI at 
age 72 revealed prominent volume loss involving brainstem 
structures with markedly decreased thickness of the ventral 
part of the pons, marked thinning of the middle cerebellar 
peduncles, and decreased transverse dimension of the brain- 
stem at the pontomesencephalic junction; moderate volume 
loss involving the cerebellar vermis and hemispheres (see Fig 
2); and moderate cerebral cortical volume loss for age. Signal 
intensity within the striatum was normal for age and there 
was no demonstrable volume loss within the striatum. PET 
with FDG (Fig 3) and FMZ was performed when the patient 
was 72 years old. 
PATIENT 2. The 71-year-old brother of Patient 1 described 
lifelong incoordination, with clumsiness in common motor 
activities, poor skills at sports, and inability to learn to ride 
a bicycle. H e  noted increased difficulty with balance and 
coordination at age 19, causing him to fall frequently. His 
incoordination progressed very slowly so that he began using 
a cane for walking at age 63. He required at walker at  age 
66 and a wheelchair by age 68. At age 54 dysarthria devel- 
oped and at  age 67 he had difficulty swallowing solids when 
his throat was dry. He had a 17-year history of sexual impo- 
tence and a long history of frequency of urination and diffi- 
culty emptying the urinary bladder. He complained of di- 
minished memory for about 10 years. The relevant past 
history included macular degeneration of undetermined 
cause, cataract surgery bilaterally with lens implantations, 
and three suicide attempts, each with a medication overdose. 
The patient did not have diabetes mellirus. 
O n  examination at age 71, the patient was in a wheelchair. 
The blood pressure was 130/70 mm Hg while he was supine, 
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Fig 3. Positron emission tomography scan showing local cerebral metabolic rate &r glucose (1CMRglc) LZS detected with (I8 FJjuoro- 
deoxyglucose in Patient 1, a 72-year-old man with the SCAl mutation (left image), in comparison with scansfiom a 68-year-old 
man with multiple system atrophy (MSA) whose diagnosis was subsequently conjrmed by autopsy examination (middle image) 
and a 74-year-old male, normal control subject (right image). The scans show horizontal sections at the level o f  the cerebellum 
and the base of the temporal and frontal lobes. The images are normalized to the LCMRglc o f  the normal control subject. The 
color bar indicates the relative rate of glucose metabolism f i r  all scans illustrated, with colors at the right end o f  the scale illustrat- 
ing high rates and at the left end low rates. The scans of the patients with SCAl and MSA show comparably reduced levels o f  
lCMRglc in the cerebellum and brainstem as compared with the normal control subject. 
declining to 122/68 mm Hg with standing. The pulse re- 
mained at 72 beadmin  in both the supine and standing 
positions. Abnormalities of extraocular movements included 
square-wave jerks, saccadic pursuits, and unsustained nystag- 
mus in the direction of gaze. Both voluntary saccadic and 
pursuit movements were slow, and overshoot dysmetria oc- 
curred. H e  had a masked face with occasional dystonic facial 
movements. Rapidly alternating tongue movements were 
moderately impaired. A moderately severe mixed dysarthria 
with prominent ataxic components along with some spastic 
and dystonic elements was detected. Titubation of the head 
was present when the patient was in the upright position, 
and alternating flexion-extension and pronation-supination 
tremors were seen in both hands with the patient at rest, on 
the left more than the right. Cogwheel rigidity was found 
at both wrists, but only with activation. Severe ataxia charac 
terized the movements of  all extremities and was exhibited 
on finger-nose-finger and heel-knee-shin tests as well as rap- 
idly alternating movements. The deep tendon reflexes includ- 
ing the ankle reflexes were grade 3 throughout and the plan- 
tar responses were extensor bilaterally. The patient was 
unable to stand unless assisted and could not walk. Sensory 
testing revealed a stocking-glove distribution of decreased 
light touch, pinprick, and vibration sensations at the fingers 
and distal to the calves. 
Genetic analysis by a commercial laboratory demonstrated 
two bands, one with 30 trinucleotide CAG repeats and the 
second with 43 repeats, indicating that one band was within 
the affected range of 42 CAG repeats or more. These find- 
ings indicate the SCAl mutation. Peripheral nerve conduc- 
tion studies at age 69 revealed mild slowing of conduction 
in both sensory and motor nerves in all four limbs. Electro- 
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myographic examination revealed minimal abnormal sponta- 
neous activity and an upper motor neuron recruitment pat- 
tern. Neuropsychological testing at age 69 revealed scores in 
the low average range (see Table 2). MRI at age 68 revealed 
moderate volume loss within brainstem structures, with 
moderately decreased thickness of the ventral aspect of the 
pons, moderate thinning of the middle cerebellar peduncles, 
and decreased transverse dimension of the brainstem at the 
pontomesencephalic junction; moderate volume loss involv- 
ing the cerebellar vermis and hemispheres; and mild cerebal 
cortical volume loss for age. Signal intensity within the stria- 
tum was normal for age and there was no demonstrable vol- 
ume loss within the striatum. PET with FDG and FMZ was 
performed when the patient was 68 years old. The results 
are given below. 
PATIENT 3. At age 40, the daughter of Patient 1 noted 
progressively increasing difficulty in walking, frequent falls, 
and incoordination when driving an automobile. Her gait 
disorder progressed so that she needed a cane for walking 
by age 44 and a walker 1 year later. At age 44 dysarthria 
and intermittent double vision developed and she began 
complaining of paresthesias in the legs. She had experienced 
difficulty remembering new information for the previous sev- 
eral years. She complained of occasional difficulty swallowing 
liquids. The patient did not have diabetes mellitus. 
Physical examination at age 47 revealed a blood pressure 
of 150/90 mm Hg and a pulse of 80 beats/min in the supine 
position, with no change in the standing position. A pseu- 
dobulbar affect was present, manifested by a tendency to 
laugh and cry easily. Abnormalities of extraocular movements 
included square-wave jerks, saccadic pursuit movements, and 
overshoot dysmetria on lateral gaze, but gaze remained con- 
jugate. Dystonic facial expressions were present. Rapidly al- 
ternating tongue movements were moderately impaired. She 
had a moderate mixed dysarthria with prominent ataxic and 
lesser degrees of spastic and dystonic components. A moder- 
ate degree of ataxia was evident on finger-nose-finger and 
heel-knee-shin testing. The limbs showed normal resistance 
to passive manipulation, even with activation. The patient 
could walk only with assistance, manifesting marked un- 
steadiness. The deep tendon reflexes were all grade 3 except 
for those at the ankles, which were grade 2. The plantar 
responses were flexor. Sensory examination revealed de- 
creased vibration sense at the toes bilaterally but no other 
abnormality. 
Genetic analysis revealed one band with 30 CAG repeats 
and the second with 4 8  repeats, indicating the SCAl muta- 
tion. Peripheral nerve conduction studies at age 45 revealed 
moderate slowing of conduction in both sensory and motor 
nerves in all four limbs. Electromyographic examination re- 
vealed a mild degree of abnormal spontaneous activity. Neu- 
ropsychological testing at age 45 revealed an average intellect 
(see Table 2). CT, performed instead of MRI because of 
claustrophobia, revealed mild thinning of the middle cerebel- 
lar peduncles, decreased transverse diameter of the brainstem 
at the pontomesencephalic junction, moderate cerebellar vol- 
ume loss, and mild cerebral cortical volume loss. There was 
no alteration in attenuation or size of the striatum. PET with 
FDG and FMZ was performed when the patient was 45 
years old. The results are given below. 
PATIENT 4. This 41-year-old man was the son of an af- 
fected brother of Patients 1 and 2 (see Fig 1). Imbalance with 
walking first developed at about age 30, when he experienced 
frequent falls. The gait disorder progressed so that by age 37 
he began using a walker at home and a wheelchair ourside 
the home. A progressive dysarthria was present for 4 or 5 
years. He recently was diagnosed with a bipolar affective dis- 
order. He reported normal sexual function and had no com- 
plaints of urinary disorder. He had a history of marked obe- 
sity since childhood and at the time of writing weighed about 
350 Ib. 
O n  physical examination, the blood pressure was 160/90 
mm Hg and the pulse was 70 beatdmin with the patient in 
the supine position, and both were unchanged when the pa- 
tient was upright. Extraocular movements showed no abnor- 
mality. A mixed ataxic-spastic dysarthria was detected. A 
mild degree of ataxia was found on finger-nose-finger testing 
and a moderate degree on heel-knee-shin testing. The stance 
was wide and the gait was ataxic with a moderate degree of 
postural instability. He could not walk on his heels, on his 
toes, or in tandem. The deep tendon reflexes were grade 3 
throughout, but 2 at the ankles. The plantar responses were 
extensor bilaterally. Sensory examination revealed no abnor- 
malities. An electromyographic and nerve conduction study 
revealed slowing of nerve conduction velocities compatible 
with a mild peripheral neuropathy. Anatomical and func- 
tional imaging studies were not performed because the pa- 
tient’s body weight exceeded the upper limit allowed. 
Positron Emission Tomography 
Table 3 summarizes the results of PET studies with 
FDG for 3 of the patients from the family with the 
SCAl mutation in the present study, in comparison t o  
data obtained from patients with dOPCA from multi- 
ple different families, MSA patients, and control sub- 
jects, adjusted to be comparable with respect to age 
and sex by analysis of covariance. The mean ICMRglc 
for the 3 patients was significantly diminished com- 
pared with control values in all regions studied: whole 
brain cortex ( p  < 0.05), caudate nucleus ( p  < 0.05), 
putamen ( p  < 0.05, two tailed), thalamus ( p  < 0.01), 
cerebellar hemispheres ( p  < 0.001), cerebellar vermis 
( p  < O.OOI), and brainstem ( p  < 0.001). The means 
for the 3 patients were also significantly lower than the 
means for the dOPCA group for the whole brain cor- 
tex ( p  < 0.05), caudate nucleus ( p  < 0.05), putamen 
( p  < O.O1) ,  thalamus ( p  < O.OI),  and brainstem 
( p  < 0.05). The means for the other two regions (cere- 
bellar hemispheres and cerebellar vermis) were also 
lower than those for the dOPCA group, but these dif- 
ferences were not statistically significant at the 5% 
level. None of the regional means for the 3 study pa- 
tients differed significantly from the corresponding 
means in the MSA group ( p  > 0.1 in all regions). 
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Table 3. Local Cerebral Metabolic Rates f o r  Glucose (mean 2 standard deviation) (mgll00 gmlmin) in 3 Family Members 
with the SCAl Mutation Compared to 17 Patients with Dominantly Inherited Olivopontocerebellar Atrophy (dOPCA) from 
Different Families, 26 Patients with Multiple System Atrophy (MSA), and 51 Normal Control Subjectsa 
SCAl dOPCA MSA Normal Controls Structure 
5.52 I- 0.67 7.36 2 1.16' 5.95 5 1.02 6.58 f 0.8'ilh Cerebral cortex 
Caudate nucleus 6.01 t 1.37 8.49 2 1.56" 6.93 2 1.45 7.54 5 1.30" 
Putamen 6.47 ? 0.91 9.41 2 1.45' 7.09 5 1.58 8.32 f 1.31'' 
Thalamus 6.31 ? 0.68 9.35 2 1.45' 7.36 ? 1.30 8.31 2 1.20' 
Cerebellar hemispheres 4.34 t 0.78 6.07 2 1.50 4.39 2 1.19 6.41 i O.8'!ld 
Cerebellar vermis 4.20 t 0.61 5.49 2 1.21 4.39 2 1.07 5.97 f 0.78" 
Brainstem 3.97 2 0.71 5.55 2 1.05b 4.07 ? 0.81 5.72 -+ 0.73d 
'Daca obtained from dOPCA and MSA patients and the normal control group have been reported previously [35]. 
"Significantly different from SCAl patients, p < 0.05. 
'Significantly different from SCAl patients, p < 0.01. 
"Significantly different from SCAl patients, p < 0.001. 
Linear discriminant analysis was performed to deter- 
mine linear combinations of the regional FDG values 
that best distinguished the MSA, dOPCA, and normal 
control groups [38]. Data from patients younger than 
40 years were excluded from the analysis to limit differ- 
ences in the age distributions. FDG values from just 
two regions-the cerebral cortex and the brainstem- 
were sufficient to account for the differences in the 
three groups, as the differences by age, sex, and FDG 
data for the other regions were not significant ( p  > 
0.1) after we controlled for these two variables. Figure 
4 displays the FDG values of the brainstem and cere- 
bral cortex for the three groups together with the 3 
SCAl patients. Data from Patient 1 are clearly most 
consistent with membership in the MSA group, and 
data from the other 2 family members are closer to 
those for the MSA patients than the dOPCA patients 
or the normal control group. The linear discriminant 
analysis yielded estimated probabilities of classification 
in each group given the values of the variables in the 
discriminant function, assuming equal prior probabili- 
ties. For Patient 1 the estimated probabilities were 
0.944 for MSA, 0.051 for dOPCA, and 0.005 for nor- 
mals. For Patient 2 the estimated probabilities were 
0.603 for MSA, 0.265 for dOPCA, and 0.132 for nor- 
mals. For Patient 3 the estimated probabilities were 
0.606 for MSA, 0.326 for dOPCA, and 0.068 for nor- 
mals. 
PET with FMZ in the 3 SCAl patients revealed k; 
means (Table 4 )  and DV means (Table 5 )  that did not 
differ significantly from the means for the dOPCA, 
MSA, or normal control groups ( p  > 0.05 for all 
groups and regions). We reported elsewhere that PET 
with FMZ revealed diminished ligand influx (4) in 
the cerebellum of patients with dOPCA and in the 
cerebellum and brainstem of patients with MSA as 
compared with normal control subjects [36]. These 
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Fig 4. Absolute levels of local cerebral metabolic rates f i r  glu- 
cose (1CMRglc) within the cerebral cortex plotted in compari- 
son with lCMRglc in the brainstem ofpatients with multiple 
system atrophy (crosses), patients with dominantly inherited 
olivopontocerebellar atrophy (stars), and normal control sub- 
jects (filled circles), and in the 3 patients with the SCAI 
mutation described in this communication (Patients I ,  2, and 
3). Data fiom all 3 patients with the SCA1 mutation are 
more closely related to the multiple system atrophy patients 
than to either the dominantly inherited olivopontocerebellar 
atrophy patients or the normal control subjects. 
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Table 4. Flumazenil Injux 
Inherited Olivopontocerebellar Atrophy (dOPCA) fiom Different Families, 19 Patients with Multiple System Atrophy (MSA), and 
20 Normal Control Subjectsb 
Structure SCAl d O P C A  MSA Normal Controls 
in 3 Family Members with the ScjZl Mutation Compared to 14 PatieTzts with Dominantly 
~- ~ _ _  
0.34 ? 0.03 0.32 t 0.06 0.29 t 0.04 0.29 t 0.05 Cerebral cortex 
Caudate nuclei 0.41 21 0.01 0.39 t 0.07 0.37 f 0.06 0.36 C 0.06 
0.45 2: 0.02 0.42 t 0.08 0.39 f 0.07 0.38 t 0.07 Putamen 
Thalamus 0.47 2: 0.003 0.47 f 0.09 0.46 2 0.07 0.43 2 0.10 
Cerebellar hemispheres 0.32 f 0.01 0.34 t 0.07 0.28 t 0.08 0.37 t 0.08 
Cerebellar vermis 0.33 5. 0.03 0.32 t 0.06 0.29 2 0.08 0.36 f 0.06 
Brainstem 0.28 ?: 0.08 0.32 t 0.06 0.27 2 0.08 0.34 2 0.08 
'Absolute levels in ml/gm/min (mean i: standard deviation). 
bData obtained from dOPCA and MSA patients and the normal control group have been reported previously [36]. 
The findings in the SCAl group are not significantly different from those in the other two groups ( p  > 0.05). Significant differences in the 
cerebellar and brainstem structures between dOPCA, MSA, and normal control groups have been reported elsewhere [36]. 
Table 5. Flumazenil Distribution Volumea in 3 Family Members with the SCAl Mutation Compared to 14 Patients with 
Dominantly Inherited Olivopontocerebellar Atrophy ( d o p a )  from Different Families, 13 Patients with Multiple-System Atrophy 
(MSA), and 20 Normal Control Subjectsb 
Structure SCAl d O P C A  MSA Normal Controls 
Cerebral cortex 5.36 ? 0.89 5.59 t 0.58 5.48 ? 1.14 5.34 t 0.90 
Caudate nuclei 3.48 t 0.68 3.07 C 0.62 3.06 f 0.66 3.10 t 0.79 
Putamen 3.83 i 0.28 3.62 2 0.59 3.92 2 0.90 3.59 t 0.64 
Thalamus 3.60 t 0.28 3.73 t 0.45 3.72 f 0.76 3.61 % 0.69 
Cerebellar hemispheres 4.67 f 1.03 4.17 C 1.07 4.69 t 1.18 4.21 i 0.67 
Cerebellar vermis 3.94 t 0.76 3.51 t 0.81 3.64 2 0.83 3.66 ? 0.57 
Brainstem 1.24 f 0.06 1.15 C 0.18 1.14 t 0.26 1.17 f 0.18 
'Absolute levels in ml/gm (mean ? standard deviation). 
'Data obtained from dOPCA and MSA patients and the normal control group have been reported previously [36]. 
None of the differences in means between the SCAl group and the other groups are significant ( p  > 0.05). The results of comparisons 
between dOPCA, MSA, and normal control groups have been reported elsewhere [36]. 
studies yielded no evidence of reduced DV in the 
brainstem, cerebellum, basal ganglia, thalamus, or cere- 
bral cortex in dOPCA or MSA subjects as compared 
with normal control subjects. 
Neuropatbological Findings o f  Patient 1 
GROSS EXAMINATION The brain weighed 1,220 gm. 
The hemispheres were symmetrical, without gyral atro- 
phy. The cerebral vessels manifested moderate patchy 
atherosclerosis. The pons and medulla were markedly 
and symmetrically atrophic, and the midbrain showed 
moderate atrophy. The cerebellar vermis and hemi- 
spheres showed severe atrophy. The brain was bisected 
and the right hemisphere was fixed in fbrmalin €or his- 
topathological examination. The left hemisphere was 
frozen for biochemical studies. 
Coronal sections of the fixed hemisphere revealed 
normal ventricular size. The cerebral cortex and the 
centrum semiovale were unremarkable. The head of the 
caudate nucleus and the lenticular nuclei were mildly 
atrophic and the caudolateral putamen was discolored. 
The thalamus and hypothalamus appeared normal. 
Sectioning of the brainstem revealed moderate pallor 
of the substantia nigra. The basis pontis and medulla 
were markedly atrophic. Sectioning of the cerebellum 
demonstrated atrophy of the cortex and central white 
matter. The spinal cord appeared unremarkable exter- 
nally and on sectioning. 
MICROSCOPlC EXAMINATION. Sections were stained 
with CV-LFB-E, PTAH, and Bielschowsky's silver 
stain and were scored for the severity of the neuronal 
loss and gliosis (Table 6). 
In the medulla, the inferior olivary nucleus showed 
severe neuronal loss and gliosis (Fig 5A) with axonal 
loss and pallor of the outflow tract in myelin stains. In 
the cerebellum, the dentate nucleus exhibited moderate 
neuronal loss and severe gliosis. The cerebellar hemi- 
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spheres showed marked loss of Purkinje cells and ac- 
companying Bergman gliosis, mild neuronal loss in the 
internal granular layer, and pallor of the white matter 
in myelin stains (Fig 5B). Similiar but milder changes 
were found in the cerebellar vermis. The pontine nuclei 
exhibited moderate neuronal loss, marked gliosis, and 
loss of transverse fibers (Fig 5C). The degenerative 
changes in the inferior olives, pons, and cerebellum 
were typical of the findings in OPCA. 
In the midbrain, there was neuronal loss and marked 
gliosis of the periaqueductal gray matter. The oculomo- 
tor and trochlear nuclei showed mild to moderate neu- 
ronal loss and gliosis, which also affected the Edinger- 
Westphal nucleus. Similar changes were found in the 
abducens and facial nuclei in the pons. In the medulla 
the hypoglossal and vagal nuclei showed mild to mod- 
erate neuronal loss and gliosis. The parahypoglossal nu- 
clei exhibited severe neuronal loss and gliosis. The ac- 
cessory cuneate and ambiguus nuclei were moderately 
affected. 
The substantia nigra exhibited neuronal loss and gli- 
osis of both pars compacta (more pronounced in the 
lateral part) (Fig 6A) and pars reticularis. The locus 
ceruleus showed mild neuronal loss and gliosis. Neu- 
ronal loss and gliosis were also found in the basal gan- 
glia, most pronounced in the head of the caudate nu- 
cleus, globus pallidus, and caudolateral portion of the 
putamen (Fig 6B). These findings are typical of the 
changes in striatonigral degeneration. 
The thalamus showed neuronal loss and gliosis in 
the anterior, dorsomedial, and ventroposterolateral nu- 
clear complexes, most severe in the latter. 
The lumbar and thoracic spinal cord regions exhib- 
ited moderate to severe neuronal loss and gliosis of 
Clarke’s column and the anterior (Fig 7A) and inter- 
mediolateral horns (Fig 7B). These changes were asso- 
ciated with mild to moderate zonal  loss and pallor of 
myelin of the cervical dorsal columns and the lateral 
corticospinal tracts of the lower lumbar region of the 
cord. Dorsal and ventral spinal roots showed mild to 
moderate diffuse loss of myelinated fibers. Lumbar dor- 
sal root ganglia displayed moderate loss of ganglion 
cells with nodules of Nageotte, as well as ganglion cells 
undergoing cystic degeneration (Fig 7C). 
The cortex of the frontal, temporal, parietal, and 
occipital lobes appeared normal. The hippocampus had 
occasional neurofibrillary tangles in the CA2 region 
and a few neuritic plaques were identified in the ento- 
rhinal cortex. The nucleus basalis of Meynert was unre- 
markable. The centrum semiovale appeared normal. 
Bielschowsky-stained sections revealed occasional 
tangle-like inclusions in oligodendroglial cells, similar 
to the GCIs described by Papp and Lantos and others 
[13-17, 19-22, 241, in the external and internal cap- 
sule, midbrain, pons, medulla, cerebellum, and spinal 
cord (Fig 8A). 
Table 6 Neuropatbologicul Findingsa of Patient I 
Anatomical Site Neuronal Loss Gliosis 
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”Scoring of the severity of neuronal loss and gliosis of involved ana- 
tomical systems: 0 = normal; + = mild; + + = moderate; + + + 
= severe. 
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Fig 5. Patient I .  Photomicrographs g t h e  (A) inferior olivay nucleus showing severe neuronal loss and dense astrogliosis (phospho- 
tungstic acid hematoxylin, X 110 before 31 % reduction); (B) cerebellum showing marked loss of Purkinje cells with accompa- 
nying Bergman gliosis and loss of  rnyelinatedjbers (cresyl violet-luxol f a t  blue-eosin, X 55 before 32% reduction); and 
(C) pontine nuclei showing moderate neuronal loss, gliosis, and loss o f  transverse fibers (jhosphotungstic acid hematoxylin, X 560 
before 32% reduction). 
IMMUNOCYTOCHEMISTRY. The GCIs were most easily 
identifiable by their positive staining for tau (Fig 8B). 
They also stained positively for ubiquitin (Fig 8C), but 
did not stain for phosphorylated neurofilament, beta- 
amyloid, or GFAP. The GCIs were seen with a fre- 
quency of no more than one per 20X field and thus 
were less common than those found in the MSA pa- 
tients of Papp and Lantos [2O]. 
Discussion 
The patients described here had a dominantly inherited 
neurodegenerative disease resulting from the SCAl 
mutation. The principal clinical features consisted of 
cerebellar ataxia accompanied by dystonia, autonomic 
insufficiency, and peripheral neuropathy. The neuro- 
pathological changes involved not only the brainstem 
and cerebellum, as in most patients with the SCAl 
disorder, but also the basal ganglia, thalamus, and in- 
termediolateral and ventral columns of the spinal cord. 
Moreover, the patient evaluated neuropathologically 
had GCIs, which are currently thought to be an impor- 
tant marker for the diagnosis of MSA [ 13-17, 19-22]. 
The distribution of neuropathological changes in the 
autopsied case was somewhat different from that seen 
in typical MSA patients, as GCIs were seen in a more 
limited number than has been described for MSA [ 13- 
17, 19-22]. Previously, GCIs were thought to be spe- 
cific for the diagnosis of MSA; however, tau- and ubi- 
quitin-positive GCIs were recently observed in other 
disorders, including corticobasal degeneration [23] and 
chromosome 17-linked dementia [39], and tau-posi- 
tive tubular astrocytic inclusions were demonstrated in 
progressive supranuclear palsy [40]. Thus, while GCIs 
are seen with greatest consistency and frequency in 
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There may be several reasons for the differences be- 
tween the patients reported in this communication and 
other patients reported with the SCAl mutation. First, 
the patients in this communication may be similar to 
others, and further analysis of patients with the SCAl 
mutation may disclose autonomic dysfunction, degen- 
eration of autonomic neurons on pathological examina- 
tion, and GCIs. Second, at least the 2 brothers (Pa- 
tients 1 and 2) might have a modifying gene that alters 
the phenotype of these patients. Third, the SCAl gene 
may contain a polymorphism that affects the pheno- 
type. Fourth, the phenotype may depend on the num- 
ber of CAG repeats, though this seems unlikely since 
in Patient 2 the number of repeats was at the lower 
end of the abnormal range. 
Patients 1 and 2 of the family described here pre- 
sented clinically with symptoms indicating progressive 
cerebellar degeneration, later accompanied by auto- 
nomic insufficiency. Neurological examination revealed 
marked cerebellar dysfunction, subtle disturbances of 
extrapyramidal and pyramidal function, and a long his- 
tory of sexual impotence. In Patient I ,  the sexual impo- 
tence could have resulted from a diabetic autonomic 
neuropathy, but Patient 2 had no evidence of diabetes 
mellitus and yet had this symptom. The other 2 family 
members evaluated (Patients 3 and 4 )  have not as yet 
shown symptoms or signs of autonomic insufficiency, 
but they are much younger than Patients 1 and 2. Pa- 
tient 3 had dystonic facial expressions and dystonic 
speech components, suggesting an extrapyramidal com- 
ponent to the findings. 
The neuropathological changes in Patient 1 included 
not only the findings of brainstem, cerebellar, and basal 
ganglia degeneration, but also changes consistent with 
a sensory and motor neuropathy and a sympathetic and 
parasympathetic disorder. The clinically and electro- 
physiologically documented sensory-motor neuropathy 
in all 4 patients corresponded to the neuropathological 
changes in Patient 1 of a sensory-motor neuronopathy, 
with loss of spinal and bulbar motor neurons and dor- 
sal root ganglion cells. In addition, Patient 1 exhibited 
loss of spinal sympathetic neurons and mild loss of 
parasympathetic neurons in the Edinger-Westphal nu- 
cleus, in keeping with the pathological changes seen 
in the Shy-Drager form of MSA [18, 47, 481. These 
neuropathological changes are not typical of diabetic 
neuropathy and are likely attributable to the hereditary 
neurodegenerative disease. Although motor neuron dis- 
ease is rarely a component of MSA [18], it was re- 
ported in one of the original cases of Shy-Drager syn- 
drome [47]. 
In Patient 1, as typically occurs in MSA, the most 
severe neuropathological changes in the striatum were 
found in the caudolateral putamen and the anterior 
caudate nucleus [ 10, 121. Relatively severe degenerative 
changes were also found in the pallidum and thalamus, 
Fig 6. Patient 1. Photomicrographs o f  the (A) hteral part o f  
substantin nigra pars compacta showing neuronal loss and 
astrogliosic (phosphotungstic acid hematoxylin, X 280 before 
28% reduction) and (B) caudolateral putamen illustrating 
moderate neuronal loss and gliosis (phosphotungstic acid hema- 
toxylin, X 280 before 27% reduction). 
MSA, they are not completely specific for this diag- 
nosis. 
Postmortem examinations have been performed on 
members of several families with the SCAl disorder 
[41-461. The findings typically involve degenerative 
changes in the cerebellum, brainstem, spinocerebellar 
pathways, and dorsal columns. Neuronal degeneration 
often includes the cranial nerve nuclei and anterior 
horn cells of the spinal cord [45],  and the striatum is 
rarely affected [46]. The extensive involvement of the 
nervous system seen in the present family, including 
the basal ganglia, cerebellum, brainstem, and inter- 
mediolateral columns of the spinal cord, and the 
finding of the GCIs have not been described previ- 
ously. 
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Fig 7. Patient 1. Photomicrographs of the (A) anterior horn of the lumbar region of the spinal cord illustrating loss of motorneu- 
rons and isomotphic gliosis, (B) intermediolateral column of the thoracic region of the spinal cord showing loss o f  sympathetic neu- 
rons and gliosis, and (C) lumbar dorsal root gangjion illustrating moderate loss of ganglion cells with nodules of Nageotte and 
vacuolar degeneration. (Cresyl violet-Luxol fast blue-eosin; A, B: X 280; C: X 5GO before 31 % reduction.) 
and it is not clear whether these changes represent 
transsynaptic degeneration secondaiy to changes in the 
striatum or unrelated degeneration. These structures 
are usually involved to a lesser extent in MSA. The 
clinical findings in Patient 2 (the brother of Patient 1) 
are similar although somewhat milder., suggesting that 
analogous neuropathological changes are present. At 
the time of writing, the third affected family member 
extensively studied remained in the early stages of the 
disorder, and the clinical studies supplemented by ana- 
tomical and functional imaging confirmed the rela- 
tively mild degree of impairment. 
The clinical findings and anatomical and functional 
imaging studies partially predicted the marked degenera- 
tive changes observed neuropathologically in Patient 1. 
Atrophy of the brainstem and cerebellum seen by MRI 
was accompanied by marked glucose hypometabolism in 
these structures as shown by PET studies with FDG. De- 
spite the moderate severity of neuronal degeneration in 
the basal ganglia on neuropathological examination, how- 
ever, the degree of atrophy in anatomical imaging studies 
was mild. PET with FDG revealed hypometabolism in 
the cerebral cortex, basal ganglia, and thalamus, and the 
degree ofhypometabolism was similar to that seen in MSA 
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Fig 8. Patient 1. Intracytopbmic oligodendroglidl inclusions in basis pontis stained with Bielschowsky i silver stain (arrow) (A), 
in external capsule immunostained with tau (B), and in cerebellum stained with ubiquitin (C). (X 2,240.) 
and much greater than that in dOPCA [35]. The FMZ 
studies disclosed no important differences in DV between 
the 3 patients with SCAl as compared with the dOPCA, 
MSA, or normal control group, suggesting relative preser- 
vation of BDZ receptors. This is in keeping with a recent 
analysis of FMZ uptake and binding in patients with 
dOPCA, sOPCA, and MSA [36]. 
Taken together, the anatomical and particularly the 
functional imaging studies indicated that the family in 
this study is different from most families with dOPCA, 
who do not show evidence of multiple system degener- 
ation. The family shows the distinctive features of mul- 
tiple system involvement, making it more akin to MSA 
than to OPCA. 
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